Dasabuvir/ombitasvir/paritaprevir/ritonavir/sorafenibVarious toxicities: 3 case reports

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2018年 / 1730卷 / 1期
关键词：
D O I：
10.1007/s40278-018-55013-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：113 / 113
相关论文
共 50 条
  • [41] Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection
    Emma D. Deeks
    Drugs, 2015, 75 : 1027 - 1038
  • [42] Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma
    Krastev, Zahariy
    Jelev, Deian
    Antonov, Krasimir
    Petkova, Tanya
    Atanasova, Evelina
    Zheleva, Nadezhda
    Tomov, Bojidar
    Boyanova, Yana
    Mateva, Lyudmila
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (08) : 2630 - 2635
  • [43] Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma
    Zahariy Krastev
    Deian Jelev
    Krasimir Antonov
    Tanya Petkova
    Evelina Atanasova
    Nadezhda Zheleva
    Bojidar Tomov
    Yana Boyanova
    Lyudmila Mateva
    World Journal of Gastroenterology, 2016, (08) : 2630 - 2635
  • [44] Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection
    Deeks, Emma D.
    DRUGS, 2015, 75 (09) : 1027 - 1038
  • [45] COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR PATIENTS WITH CHRONIC HCV IN THE NETHERLANDS
    Gaultney, J.
    de Knegt, R. J.
    Fassler, P.
    Visser, S.
    Johnson, S.
    VALUE IN HEALTH, 2015, 18 (07) : A588 - A588
  • [46] Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs for Substance Abuse
    King, Jennifer R.
    Menon, Rajeev M.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (02): : 201 - 205
  • [47] Dasabuvir/ombitasvir/paritaprevir/ritonavirAcute interstitial nephritis: case report
    Reactions Weekly, 2023, 1971 (1) : 97 - 97
  • [48] Paritaprevir/ritonavir/ombitasvir plus dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report
    Puglisi, G. M.
    Smith, S. M.
    Jankovich, R. D.
    Ashby, C. R.
    Jodlowski, T. Z.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (01) : 115 - 118
  • [49] Ombitasvir/paritaprevir/ritonavir/tacrolimus interactionNephrotoxicity: case report
    Reactions Weekly, 2016, 1628 (1) : 280 - 280
  • [50] Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage
    Talal, Andrew H.
    Dumas, Emily O.
    Bauer, Barbara
    Rejman, Richard M.
    Ocque, Andrew
    Morse, Gene D.
    Lucic, Danijela
    Cloherty, Gavin A.
    King, Jennifer
    Zha, Jiuhong
    Zhang, Hongtao
    Cohen, Daniel E.
    Shulman, Nancy
    Pawlotsky, Jean-Michel
    Hezode, Christophe
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (03): : 474 - 482
12345